Polivy Approved for Previously Untreated DLBCL, Not Otherwise Specified, or High-Grade B-Cell Lymphoma

The FDA approved polatuzumab vedotin-piiq (Polivy, Genentech) with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma and who have an International Prognostic Index (IPI) score of 2 or greater.

Approval was based on POLARIX (ClinicalTrials.gov Identifier: NCT03274492), a randomized, double-blind, placebo-controlled trial in 879 patients